Fiche publication
Date publication
octobre 2023
Journal
Tissue engineering. Part A
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GILLET Pierre
,
Pr MAINARD Didier
Tous les auteurs :
Messaoudi O, Henrionnet C, Courtial EJ, Grossin L, Mainard D, Galois L, Loeuille D, Marquette C, Gillet P, Pinzano A
Lien Pubmed
Résumé
The bioextrusion of mesenchymal stromal cells (MSCs) directly seeded in a bioink enables the production of 3D constructs, promoting their chondrogenic differentiation. Our study aimed to evaluate the effect of different type I collagen concentrations in the bioink on MSCs' chondrogenic differentiation. We printed 3D constructs using an alginate, gelatin, and fibrinogen-based bioink cellularized with MSCs, with four different quantities of type I collagen addition (0.0, 0.5, 1.0, and 5.0 mg per bioink syringe). We assessed the influence of the bioprinting process, the bioink composition, and the growth factor (TGF-ꞵ1) on the MSCs' survival rate. We confirmed the biocompatibility of the process and the bioinks' cytocompatibility. We evaluated the chondrogenic effects of TGF-ꞵ1 and collagen addition on the MSCs' chondrogenic properties through macroscopic observation, shrinking ratio, RT-PCR, glycosaminoglycan synthesis, histology, and type II collagen immunohistochemistry. The bioink containing 0.5 mg of collagen produces the richest hyaline-like extracellular matrix, presenting itself as a promising tool to recreate the superficial layer of hyaline cartilage. The bioink containing 5.0 mg of collagen enhances the synthesis of a calcified matrix, making it a good candidate for mimicking the calcified cartilaginous layer. Type I collagen thus allows the dose-dependent design of specific hyaline-cartilage layers.
Référence
Tissue Eng Part A. 2023 10 26;:
